Suggestions
Rob de Ree
CEO at NorthSea Therapeutics B.V.
Professional Background
Rob de Ree is a seasoned executive with a wealth of experience in the pharmaceutical and medical device industries. With a remarkable career spanning several organizations, Rob has demonstrated his leadership prowess and strategic insight in various high-stakes roles. Currently, he serves as the CEO of NorthSea Therapeutics B.V., a company dedicated to developing innovative therapies for metabolic diseases. Under his stewardship, NorthSea Therapeutics is committed to addressing critical healthcare needs through cutting-edge research and development.
Rob's extensive career also includes serving as an Operating Partner at Biogeneration Ventures, where he played a significant role in guiding investments in emerging life science companies. His expertise in business development and strategic planning has made him an invaluable asset in fostering innovation and growth within the biotech sector.
In addition to his role at Biogeneration Ventures, Rob has contributed his strategic insights as a member of the Supervisory Board at Mellon Medical B.V. and as the Chairman of the Supervisory Board at Ventinova Medical. His leadership capabilities were further showcased during his tenure as the General Manager at Dezima Pharma, where he successfully navigated the complexities of the pharmaceutical landscape, culminating in the acquisition of Dezima by Amgen.
Throughout his career, Rob has held several prominent positions, including Vice President of Critical Care Non-Invasive at Edwards Lifesciences, CEO at BMEYE, and numerous roles at Medtronic, including European Marketing Director. Each position has allowed him to hone his skills in sales and marketing, product development, and strategic management, driving remarkable growth and operational efficiencies.
Education and Achievements
Rob de Ree earned his Master's degree in Pharmacy from the Rijksuniversiteit Groningen, a prestigious institution known for its rigorous academic standards and emphasis on research. His educational background laid a strong foundation for his subsequent career in pharmaceuticals and healthcare.
One of Rob's notable achievements was his integral role in the development and commercialization of innovative medical devices and therapies that have enhanced patient outcomes. As CEO at Dezima Pharma, he led the charge in developing breakthrough treatments for dyslipidemia, ultimately resulting in a strategic acquisition that signified a successful exit for investors and stakeholders alike.
Rob's influence extends beyond corporate management; he is passionate about mentorship and helping emerging leaders in the industry grow. His experience on the supervisory boards demonstrates his commitment to shaping the future of healthcare by guiding innovative companies, ensuring they have the support and resources they need to thrive.
Achievements
- CEO of NorthSea Therapeutics B.V.: Leading a company focused on transforming the treatment of metabolic diseases through innovative therapeutic solutions.
- Operating Partner at Biogeneration Ventures: Steering investment strategies and business development for life science startups, leveraging industry expertise to identify lucrative opportunities.
- Chairman of Supervisory Board at Ventinova Medical: Providing strategic oversight and guidance to enhance the company's direction in the medical device sector.
- General Manager at Dezima Pharma (Acquired by Amgen): Successfully navigating the organization through its acquisition and driving growth in innovative treatments for dyslipidemia.
- Vice President, Edwards Lifesciences: Spearheading critical care initiatives and fostering non-invasive treatment technologies.
- Extensive Experience at Medtronic: Holding multiple roles that contributed to successful product launches and marketing campaigns across Europe, enabling increased market penetration and brand visibility.
With a career dedicated to advancing healthcare and a passion for innovation, Rob de Ree exemplifies leadership in the pharmaceutical and medical device industries. His extensive experience, from strategic partnerships to executive leadership roles, has positioned him as a key player in shaping the future of medicinal therapies and enhancing patient care.
